Business Wire

Saudi Arabia Approves Oncothermia, the Latest Technology in Cancer Treatment

Del

After being approved in over 30 countries, the Saudi Food and Drug Authority (SFDA) approved the use of Oncothermia (modulated electro-hyperthermia, mEHT), the latest complementary cancer treatment technology.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170803005553/en/

New cancer treatment machine in Saudi Arabia (Photo: AETOS Wire)

New cancer treatment machine in Saudi Arabia (Photo: AETOS Wire)

The treatment gives cancer patients enhanced quality of life, improved survival rates, and comfort during the various stages of treatment as well as promotes their physical and psychological wellbeing.

“Oncothermia is basically developed from the traditional oncological hyperthermia method, one of the oldest methods in fighting diseases,” said Eng. Hani Mohammed Saeed Yamani, General Manager of HYE, Exclusive Agents of Oncothermia devices in GCC.

“Oncothermia does not raise the body temperature. It raises tumor cells temperature to 43⁰ C, while keeping the surrounding healthy tissues at core body temperature, or slightly higher, unlike conventional hyperthermia methods,” he said.

“The new technology uses a modulated electric field of 150 W, with a carrier frequency of 13.56 MHz that is generated by electrodes,” Yamani explained. “The moving electrode is positioned in accordance with the body area being treated, while a second, stationary electrode always remains in a fixed position below the patient.”

Unlike the traditional hyperthermia, Oncothermia targets only the tumor area, leaving the surrounding tissue unaffected. Conductivity in malignant cells is higher than that of normal cells, which means that the electric field applied will reach all malignant cells, increasing their temperature.

Yamani pointed out that the treatment is safe and non-poisonous as it uses low energy levels and frequency fields. It provides various treatment options using Oncothermia for advanced incurable tumors, whether or not they can be surgically removed, as well as recurrent and metastatic cancers and prostate cancer.

Oncothermia is not a stand-alone cancer treatment; it is provided as a complementary treatment. Studies have shown that applying Oncothermia together with radiation therapy or chemotherapy, can be highly effective, and can strongly enhance the effectiveness of other treatments.

Consultants in the Saudi Arabia are currently being introduced to this new technology and its benefits, as well as the research conducted by Prof. András Szász, the inventor of the treatment, to help ease the pain of cancer patients and assist in their healing process.

*Source: AETOS Wire

Contact information

Headline Communication
Feras Adel Al Maddah, +9665606960606
fmaddah@headlineme.com
or
HYE
Eng. Hani Ymani, +966505818834
INFO@HYE.COM.SA
WWW.HYE.COM.SA

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lenovo Attains Status as Largest Global Provider of TOP500 Supercomputers25.6.2018 07:01Pressemelding

Today, at the International Supercomputing Conference (ISC) in Frankfurt, Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY) continued its global momentum, becoming the world’s largest TOP500 supercomputing provider measured by the number of systems ranked on the TOP500 list. 117 of the 500 most powerful supercomputers included in the TOP500 are Lenovo installations, meaning nearly one out of every four systems (23.4 percent) on the prestigious list is a Lenovo solution. “Last year, we set a goal to become the world’s largest provider of TOP500 computing systems by 2020. We have reached that goal two years ahead of our original plan,” said Kirk Skaugen, President of Lenovo Data Center Group. “This distinction is a testament to our commitment to prioritize customer satisfaction, deliver cutting edge innovation and performance and be the world’s most trusted data center partner. We are motivated every day by the scientists and their groundbreaking research as we work together to solve hum

XebiaLabs Unveils “Periodic Table of DevOps Tools” v.3 at DevOps Enterprise Summit London 201825.6.2018 07:00Pressemelding

XebiaLabs, the recognized leader in Enterprise DevOps and Continuous Delivery software, today announced the release of The Periodic Table of DevOps Tools v.3, an update of its free, industry-recognized DevOps landscape tool. The latest release of this acclaimed tool features 52 new DevOps tools, a new design, and the addition of categories, such as Analytics and AIOps, to reflect the expanding DevOps tools and technologies market. In addition, users can select a tool in the Periodic Table and immediately visualize it in the software delivery pipeline using XebiaLabs’ integrated DevOps Diagram Generator. DevOps pipeline diagrams can be easily customized, downloaded, printed, and shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005106/en/ XebiaLabs Unveils “Periodic Table of DevOps Tools” v.3 at DevOps Enterprise Summit London 2018 (Graphic: Business Wire) Given the fast pace at which new DevOps tools become availa

Enterprise DevOps for the Cloud25.6.2018 07:00Pressemelding

XebiaLabs, the recognized leader in enterprise DevOps and Continuous Delivery software, today announced a DevOps framework that provides a smooth pathway to the cloud for companies who are moving applications to cloud-based resources on a large scale. The framework connects enterprise DevOps practices with common cloud management functionality and provides an essential foundation as enterprises accelerate their transformations to cloud-based applications. Cloud Does Not Equal DevOps Easy access to public cloud technologies creates a common misconception: moving to the cloud will not only provide more flexible and scalable infrastructure at a lower cost, but it will also accelerate the delivery of applications to the customer. In reality, moving to the cloud is just one step in that journey. Enterprises that are looking to improve and accelerate software delivery are implementing DevOps practices that span the entire software delivery value stream. These practices are generally unrelate

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,